お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は自己免疫性溶血性貧血治療薬市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートは自己免疫性溶血性貧血治療薬の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界の自己免疫性溶血性貧血治療薬市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートは自己免疫性溶血性貧血治療薬のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別に自己免疫性溶血性貧血治療薬市場を分類しています。本研究に含まれる主な企業は：Amneal Pharmaceuticals Inc、Baxter International Inc、F. Hoffmann-La Roche Ltd、Incyte Corp、Kezar Life Sciences Inc、Pfizer Inc、Rigel Pharmaceuticals Inc、Sanofi、Teva Pharmaceutical Industries Ltd、Horizo​​n、Genentech、Zydus Cadila、Concord Biotech

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Corticosteroids
    Monoclonal Antibodies
    Others

用途別の市場セグメント：
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

本レポートの詳細内容
世界の自己免疫性溶血性貧血治療薬市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、自己免疫性溶血性貧血治療薬タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業の自己免疫性溶血性貧血治療薬収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の自己免疫性溶血性貧血治療薬市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、自己免疫性溶血性貧血治療薬市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

自己免疫性溶血性貧血治療薬のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：自己免疫性溶血性貧血治療薬のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：自己免疫性溶血性貧血治療薬の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章自己免疫性溶血性貧血治療薬企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：自己免疫性溶血性貧血治療薬の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：自己免疫性溶血性貧血治療薬の主要企業の概要を提供し、製品の説明と仕様、自己免疫性溶血性貧血治療薬の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Autoimmune Hemolytic Anemia (AHA) is also called immune hemolytic anemia. It is an immune and rare red blood cell disorder. Autoimmune hemolytic anemia occurs when the immune system makes antibodies that attack red blood cells in the body. This decreases the number of red blood cells, resulting to hemolytic anemia.
Market Analysis and Insights: Global Autoimmune Hemolytic Anemia Therapeutics Market
The global Autoimmune Hemolytic Anemia Therapeutics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Covers:
This report presents an overview of global market for Autoimmune Hemolytic Anemia Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Autoimmune Hemolytic Anemia Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Autoimmune Hemolytic Anemia Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Autoimmune Hemolytic Anemia Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Autoimmune Hemolytic Anemia Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Autoimmune Hemolytic Anemia Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Amneal Pharmaceuticals Inc, Baxter International Inc, F. Hoffmann-La Roche Ltd, Incyte Corp, Kezar Life Sciences Inc, Pfizer Inc, Rigel Pharmaceuticals Inc, Sanofi and Teva Pharmaceutical Industries Ltd, etc.
Market Segmentation
By Company
    Amneal Pharmaceuticals Inc
    Baxter International Inc
    F. Hoffmann-La Roche Ltd
    Incyte Corp
    Kezar Life Sciences Inc
    Pfizer Inc
    Rigel Pharmaceuticals Inc
    Sanofi
    Teva Pharmaceutical Industries Ltd
    Horizo​​n
    Genentech
    Zydus Cadila
    Concord Biotech

Segment by Type
    By Drug Class
        Corticosteroids
        Monoclonal Antibodies
        Others
    By Disease Type
        Cold Antibody Hemolytic Anemia
        Warm Antibody Hemolytic Anemia

Segment by Application
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Autoimmune Hemolytic Anemia Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Autoimmune Hemolytic Anemia Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Autoimmune Hemolytic Anemia Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Autoimmune Hemolytic Anemia Therapeutics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Corticosteroids
    Table 3. Key Players of Monoclonal Antibodies
    Table 4. Key Players of Others
    Table 5. Global Autoimmune Hemolytic Anemia Therapeutics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 6. Global Autoimmune Hemolytic Anemia Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Autoimmune Hemolytic Anemia Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 8. Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Region (2019-2024)
    Table 9. Global Autoimmune Hemolytic Anemia Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 10. Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Region (2025-2030)
    Table 11. Autoimmune Hemolytic Anemia Therapeutics Market Trends
    Table 12. Autoimmune Hemolytic Anemia Therapeutics Market Drivers
    Table 13. Autoimmune Hemolytic Anemia Therapeutics Market Challenges
    Table 14. Autoimmune Hemolytic Anemia Therapeutics Market Restraints
    Table 15. Global Autoimmune Hemolytic Anemia Therapeutics Revenue by Players (2019-2024) & (US$ Million)
    Table 16. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Share by Players (2019-2024)
    Table 17. Global Top Autoimmune Hemolytic Anemia Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Autoimmune Hemolytic Anemia Therapeutics as of 2023)
    Table 18. Global Autoimmune Hemolytic Anemia Therapeutics Industry Ranking 2022 VS 2023 VS 2024
    Table 19. Global 5 Largest Players Market Share by Autoimmune Hemolytic Anemia Therapeutics Revenue (CR5 and HHI) & (2019-2024)
    Table 20. Global Key Players of Autoimmune Hemolytic Anemia Therapeutics, Headquarters and Area Served
    Table 21. Global Key Players of Autoimmune Hemolytic Anemia Therapeutics, Product and Application
    Table 22. Global Key Players of Autoimmune Hemolytic Anemia Therapeutics, Product and Application
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Autoimmune Hemolytic Anemia Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 25. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Type (2019-2024)
    Table 26. Global Autoimmune Hemolytic Anemia Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 27. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Type (2025-2030)
    Table 28. Global Autoimmune Hemolytic Anemia Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 29. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Share by Application (2019-2024)
    Table 30. Global Autoimmune Hemolytic Anemia Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 31. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Share by Application (2025-2030)
    Table 32. North America Autoimmune Hemolytic Anemia Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 33. North America Autoimmune Hemolytic Anemia Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 34. North America Autoimmune Hemolytic Anemia Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 35. North America Autoimmune Hemolytic Anemia Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 36. North America Autoimmune Hemolytic Anemia Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 37. North America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 38. North America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 39. Europe Autoimmune Hemolytic Anemia Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 40. Europe Autoimmune Hemolytic Anemia Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 41. Europe Autoimmune Hemolytic Anemia Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 42. Europe Autoimmune Hemolytic Anemia Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 43. Europe Autoimmune Hemolytic Anemia Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Europe Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Europe Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 46. China Autoimmune Hemolytic Anemia Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 47. China Autoimmune Hemolytic Anemia Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 48. China Autoimmune Hemolytic Anemia Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 49. China Autoimmune Hemolytic Anemia Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 50. Asia Autoimmune Hemolytic Anemia Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 51. Asia Autoimmune Hemolytic Anemia Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 52. Asia Autoimmune Hemolytic Anemia Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 53. Asia Autoimmune Hemolytic Anemia Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 54. Asia Autoimmune Hemolytic Anemia Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 55. Asia Autoimmune Hemolytic Anemia Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 56. Asia Autoimmune Hemolytic Anemia Therapeutics Market Size by Region (2025-2030) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Autoimmune Hemolytic Anemia Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 62. Middle East, Africa, and Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 64. Amneal Pharmaceuticals Inc Company Details
    Table 65. Amneal Pharmaceuticals Inc Business Overview
    Table 66. Amneal Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Product
    Table 67. Amneal Pharmaceuticals Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024) & (US$ Million)
    Table 68. Amneal Pharmaceuticals Inc Recent Developments
    Table 69. Baxter International Inc Company Details
    Table 70. Baxter International Inc Business Overview
    Table 71. Baxter International Inc Autoimmune Hemolytic Anemia Therapeutics Product
    Table 72. Baxter International Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024) & (US$ Million)
    Table 73. Baxter International Inc Recent Developments
    Table 74. F. Hoffmann-La Roche Ltd Company Details
    Table 75. F. Hoffmann-La Roche Ltd Business Overview
    Table 76. F. Hoffmann-La Roche Ltd Autoimmune Hemolytic Anemia Therapeutics Product
    Table 77. F. Hoffmann-La Roche Ltd Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024) & (US$ Million)
    Table 78. F. Hoffmann-La Roche Ltd Recent Developments
    Table 79. Incyte Corp Company Details
    Table 80. Incyte Corp Business Overview
    Table 81. Incyte Corp Autoimmune Hemolytic Anemia Therapeutics Product
    Table 82. Incyte Corp Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024) & (US$ Million)
    Table 83. Incyte Corp Recent Developments
    Table 84. Kezar Life Sciences Inc Company Details
    Table 85. Kezar Life Sciences Inc Business Overview
    Table 86. Kezar Life Sciences Inc Autoimmune Hemolytic Anemia Therapeutics Product
    Table 87. Kezar Life Sciences Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024) & (US$ Million)
    Table 88. Kezar Life Sciences Inc Recent Developments
    Table 89. Pfizer Inc Company Details
    Table 90. Pfizer Inc Business Overview
    Table 91. Pfizer Inc Autoimmune Hemolytic Anemia Therapeutics Product
    Table 92. Pfizer Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024) & (US$ Million)
    Table 93. Pfizer Inc Recent Developments
    Table 94. Rigel Pharmaceuticals Inc Company Details
    Table 95. Rigel Pharmaceuticals Inc Business Overview
    Table 96. Rigel Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Product
    Table 97. Rigel Pharmaceuticals Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024) & (US$ Million)
    Table 98. Rigel Pharmaceuticals Inc Recent Developments
    Table 99. Sanofi Company Details
    Table 100. Sanofi Business Overview
    Table 101. Sanofi Autoimmune Hemolytic Anemia Therapeutics Product
    Table 102. Sanofi Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024) & (US$ Million)
    Table 103. Sanofi Recent Developments
    Table 104. Teva Pharmaceutical Industries Ltd Company Details
    Table 105. Teva Pharmaceutical Industries Ltd Business Overview
    Table 106. Teva Pharmaceutical Industries Ltd Autoimmune Hemolytic Anemia Therapeutics Product
    Table 107. Teva Pharmaceutical Industries Ltd Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024) & (US$ Million)
    Table 108. Teva Pharmaceutical Industries Ltd Recent Developments
    Table 109. Horizo​​n Company Details
    Table 110. Horizo​​n Business Overview
    Table 111. Horizo​​n Autoimmune Hemolytic Anemia Therapeutics Product
    Table 112. Horizo​​n Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024) & (US$ Million)
    Table 113. Horizo​​n Recent Developments
    Table 114. Genentech Company Details
    Table 115. Genentech Business Overview
    Table 116. Genentech Autoimmune Hemolytic Anemia Therapeutics Product
    Table 117. Genentech Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024) & (US$ Million)
    Table 118. Genentech Recent Developments
    Table 119. Zydus Cadila Company Details
    Table 120. Zydus Cadila Business Overview
    Table 121. Zydus Cadila Autoimmune Hemolytic Anemia Therapeutics Product
    Table 122. Zydus Cadila Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024) & (US$ Million)
    Table 123. Zydus Cadila Recent Developments
    Table 124. Concord Biotech Company Details
    Table 125. Concord Biotech Business Overview
    Table 126. Concord Biotech Autoimmune Hemolytic Anemia Therapeutics Product
    Table 127. Concord Biotech Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024) & (US$ Million)
    Table 128. Concord Biotech Recent Developments
    Table 129. Research Programs/Design for This Report
    Table 130. Key Data Information from Secondary Sources
    Table 131. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Autoimmune Hemolytic Anemia Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Type: 2023 VS 2030
    Figure 3. Corticosteroids Features
    Figure 4. Monoclonal Antibodies Features
    Figure 5. Others Features
    Figure 6. Global Autoimmune Hemolytic Anemia Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 7. Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Application: 2023 VS 2030
    Figure 8. Hospital Pharmacies Case Studies
    Figure 9. Retail Pharmacies Case Studies
    Figure 10. Online Pharmacies Case Studies
    Figure 11. Autoimmune Hemolytic Anemia Therapeutics Report Years Considered
    Figure 12. Global Autoimmune Hemolytic Anemia Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 13. Global Autoimmune Hemolytic Anemia Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Region: 2023 VS 2030
    Figure 15. Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Players in 2023
    Figure 16. Global Top Autoimmune Hemolytic Anemia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Autoimmune Hemolytic Anemia Therapeutics as of 2023)
    Figure 17. The Top 10 and 5 Players Market Share by Autoimmune Hemolytic Anemia Therapeutics Revenue in 2023
    Figure 18. North America Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 19. North America Autoimmune Hemolytic Anemia Therapeutics Market Share by Type (2019-2030)
    Figure 20. North America Autoimmune Hemolytic Anemia Therapeutics Market Share by Application (2019-2030)
    Figure 21. North America Autoimmune Hemolytic Anemia Therapeutics Market Share by Country (2019-2030)
    Figure 22. United States Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Canada Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Europe Autoimmune Hemolytic Anemia Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 25. Europe Autoimmune Hemolytic Anemia Therapeutics Market Share by Type (2019-2030)
    Figure 26. Europe Autoimmune Hemolytic Anemia Therapeutics Market Share by Application (2019-2030)
    Figure 27. Europe Autoimmune Hemolytic Anemia Therapeutics Market Share by Country (2019-2030)
    Figure 28. Germany Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. France Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. U.K. Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Italy Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Russia Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Nordic Countries Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. China Autoimmune Hemolytic Anemia Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 35. China Autoimmune Hemolytic Anemia Therapeutics Market Share by Type (2019-2030)
    Figure 36. China Autoimmune Hemolytic Anemia Therapeutics Market Share by Application (2019-2030)
    Figure 37. Asia Autoimmune Hemolytic Anemia Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 38. Asia Autoimmune Hemolytic Anemia Therapeutics Market Share by Type (2019-2030)
    Figure 39. Asia Autoimmune Hemolytic Anemia Therapeutics Market Share by Application (2019-2030)
    Figure 40. Asia Autoimmune Hemolytic Anemia Therapeutics Market Share by Region (2019-2030)
    Figure 41. Japan Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. South Korea Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. China Taiwan Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. India Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Australia Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Middle East, Africa, and Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 48. Middle East, Africa, and Latin America Autoimmune Hemolytic Anemia Therapeutics Market Share by Type (2019-2030)
    Figure 49. Middle East, Africa, and Latin America Autoimmune Hemolytic Anemia Therapeutics Market Share by Application (2019-2030)
    Figure 50. Middle East, Africa, and Latin America Autoimmune Hemolytic Anemia Therapeutics Market Share by Country (2019-2030)
    Figure 51. Brazil Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Mexico Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Turkey Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Saudi Arabia Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Israel Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. GCC Countries Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Amneal Pharmaceuticals Inc Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024)
    Figure 58. Baxter International Inc Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024)
    Figure 59. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024)
    Figure 60. Incyte Corp Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024)
    Figure 61. Kezar Life Sciences Inc Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024)
    Figure 62. Pfizer Inc Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024)
    Figure 63. Rigel Pharmaceuticals Inc Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024)
    Figure 64. Sanofi Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024)
    Figure 65. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024)
    Figure 66. Horizo​​n Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024)
    Figure 67. Genentech Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024)
    Figure 68. Zydus Cadila Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024)
    Figure 69. Concord Biotech Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2019-2024)
    Figure 70. Bottom-up and Top-down Approaches for This Report
    Figure 71. Data Triangulation
    Figure 72. Key Executives Interviewed